A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure

A randomized trial to evaluate the cardioprotective effect of the uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure - A randomized trial to evaluate the cardioprotective effect of uric acid-lowering therapy for hyperuricemia in patients with chronic heart failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000426

Enrollment

Registered

2006-06-01

Start date

2006-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia in patients with chronic heart failure

Interventions

Benzbromarone (25-75 mg daily) for 4 months Allopurinol (100-300mg daily) for 4 months Life-style modification

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who have stable left ventricular systolic dysfunction (fractional shortening <25%) and hyperuricemia (serum uric acid >=8.0 mg/dl)

Exclusion criteria

Exclusion criteria: 1) Gouty arthritis or tophus 2) Patients who have already taken the uric acid-lowering drugs 3) Renal dysfunction (serum creatinin >=2.0 mg/dl) 4) Urinary or renal calculus 5) Hepatic dysfunction (GPT (ALT) >=50 IU/l) 6) Patients who do not agree and whom physician judges inappropriate to this trial for any reason

Design outcomes

Primary

Measure	Time frame
1) The plasma BNP levels 2) The plasma levels of markers of oxidative stress 3) The plasma levels of pro-inflammatory cytokines	—

Secondary

Measure	Time frame
1) NYHA functional class 2) Hospitalizaion for worsening heart failure	—

Countries

Japan

Contacts

Public ContactMasanori Asakura

National Cardiovascular Center Cardiovascular Clinical Research Center

asamasa@xd5.so-net.ne.jp06-6833-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026